MedPharm

MedPharm

Founded in 1999 by a group led by Andrew Muddle, MedPharm emerged from Oxford's academic ecosystem as a dedicated formulation development house. The firm focuses exclusively on topical, transdermal, and inhaled drug delivery — a niche that most major pharmaceutical companies outsource rather than staff internally. MedPharm's early work centered on optimizing dermatological creams, but its model soon expanded to carve out a position as the go-to partner for complex reformulations and generic-differentiation strategies. MedPharm's model covers the full pre-clinical formulation lifecycle: excipient screening, prototype development, analytical testing, and manufacture of clinical trial batches. Its core expertise spans semi-solid dosage forms — creams, ointments, gels — alongside transdermal patches, buccal films, and inhaled formulations. The firm has publicly cited clients across Big Pharma, specialty generics, and biotech, with named relationships including a long-running topical reformulation program for a leading Pfizer dermatology asset and analytical support for GSK's respiratory pipeline. Its geographic reach extends across Europe and North America, with a particular concentration in the UK and US. MedPharm's footprint has grown beyond its Guildford headquarters to include a significant US operation in Durham, North Carolina. In April 2022, the firm appointed Eugene Ciolfi as President of its US division, signaling an expansion of its North American client-servicing capability (per the firm, April 2022). While the firm remains privately held and does not disclose headcount, it has historically described itself as operating at the intersection of CRO and specialty CDMO, running R&D programs alongside its manufacturing capabilities. What structurally separates MedPharm from a generic CRO is its proprietary in vitro penetration-testing technology, which models drug absorption through human tissue without requiring animal or early-stage human trials. This creates a data advantage for clients and locks in early-stage formulation work that traditional CROs and CDMOs struggle to replicate. MedPharm's succession appears stable, with the founding scientific leadership deeply embedded in the firm's IP and client relationships.